Roche and Janssen Biotech Inc. are collaborating to bring the next level of precision medicine to patients. By creating companion diagnostics for targeted therapies, Roche and Janssen are striving to advance research and innovation and make treatment more precise. This expanded collaboration aims to improve patient outcomes and provide better care.
Roche and Janssen have expanded their agreement to explore the potential of precision medicine, incorporating a range of companion diagnostics technologies, including immunohistochemistry, digital pathology, next-generation sequencing, polymerase chain reaction and immunoassays. This collaboration promises to bring a wealth of new opportunities for both companies to innovate and develop treatments tailored to individual patient needs.
Roche Diagnostics is leading the charge in revolutionizing healthcare through collaboration with industry leaders around the world. As Head of Pathology Lab at Roche Diagnostics, Jill German is at the forefront of this effort, with the goal of improving personalized healthcare through the development of more targeted, effective tests. Together, we are taking strides towards making better treatments more accessible to those who need them.
This collaboration will open the door to exciting new projects, such as data and tissue image analysis, and the development of a novel IHC assay for patient identification and enrollment for personalized treatment. By combining our expertise, we can explore and create innovative solutions that have the potential to revolutionize healthcare.
Roche, founded in 1896 in Basel, Switzerland, is the world’s largest biotechnology company and global leader in in-vitro diagnostics. Our mission is to discover and develop medicines and diagnostics that improve and save the lives of people around the world. We are pioneers in personalised healthcare and strive to transform how healthcare is delivered to make a greater impact. To provide the best care for each individual, we collaborate with a range of stakeholders and harness the power of Diagnostics and Pharma with data insights from clinical practice.
For the past thirteen years, Roche has been consistently recognised as one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices. We are proud to have achieved this distinction, which reflects our ongoing commitment to pursue a long-term perspective in all we do and to improve healthcare access with local partners around the world.
Genentech, based in the United States, is a part of the global pharmaceutical giant, Roche Group. With Roche being the majority shareholder, Genentech is also connected to the Japanese pharma giant Chugai Pharmaceutical.